Skip to content

13F-HR filed by Camber Capital Management LP

Camber Capital Management LP filed this 13F-HR for the quarter ended 2019-06-30, filed 2019-08-14, with 31 holding rows worth $2,145,433,000.

Accession
0001654954-19-009455
Filed
2019-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2019

A holdings report, 31 entries on the cover page, a total value of $2,145,433,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,145,433,000 with VALUE read as thousands by filing date, 13F file number 028-13745. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPY78462F103SHS1,000,000$293,000,000thousands by filing dateput
ALLERGAN PLCG0177J108SHS1,250,000$209,288,000thousands by filing date
MYLAN NVN59465109SHS EURO9,250,000$176,120,000thousands by filing date
DAVITA INC COM23918K108Stock2,000,000$112,520,000thousands by filing date
PERRIGO CO PLC SHSG97822103Stock2,000,000$95,240,000thousands by filing date
BROOKDALE SR LIVING INC112463104COM12,500,000$90,125,000thousands by filing date
NEKTAR THERAPEUTICS640268108COM2,500,000$88,950,000thousands by filing date
UNIVERSAL HLTH SVCS INC CL B913903100Stock650,000$84,754,000thousands by filing date
ALLERGAN PLCG0177J108SHS500,000$83,715,000thousands by filing datecall
HCA Healthcare Inc40412C101COM600,000$81,102,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM500,000$75,975,000thousands by filing date
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR650,000$74,848,000thousands by filing date
Gilead Sciences,Inc.375558103COM1,000,000$67,560,000thousands by filing date
MEDICINES CO584688105COM1,700,000$61,999,000thousands by filing date
TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS881624209ADR6,500,000$59,995,000thousands by filing date
ZYMEWORKS INC98985W102COM2,600,000$57,200,000thousands by filing date
MYLAN NVN59465109SHS EURO3,000,000$57,120,000thousands by filing datecall
ALEXION PHARMACEUTICALS INC015351109COM400,000$52,392,000thousands by filing date
TENET HEALTHCARE CORP COM NEW88033G407Stock2,500,000$51,650,000thousands by filing date
Bristol-Myers Squibb Company110122108COM1,000,000$45,350,000thousands by filing date
MOMENTA PHARMACEUTICALS INC60877T100COM3,500,000$43,575,000thousands by filing date
ATARA BIOTHERAPEUTICS INC COM NEW046513107Stock2,000,000$40,220,000thousands by filing date
AMAG PHARMACEUTICALS INC00163U106COM3,000,000$29,970,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock367,529$28,689,000thousands by filing date
SYNTHORX INC COM87167A103Stock1,862,116$25,157,000thousands by filing date
GLAXOSMITHKLINE PLC-ADR37733W105SPONSORED ADR500,000$20,010,000thousands by filing date
CYCLERION THERAPEUTICS INC23255M105COM1,561,915$17,884,000thousands by filing date
TG THERAPEUTICS INC COM88322Q108Stock1,000,000$8,650,000thousands by filing date
SUTRO BIOPHARMA INC869367102COM600,000$6,828,000thousands by filing date
ALKERMES PLCG01767105SHS188,281$4,244,000thousands by filing date
SURGERY PARTNERS INC86881A100COM160,084$1,303,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001654954-19-009455this filing2019-08-14acceptance time not in the bulk data set